A study has found two doses of GlaxoSmithKline's ($GSK) Rotarix is as effective as a three-shot regimen of Merck's ($MRK) RotaTeq in preventing severe rotavirus-associated gastroenteritis. The data dampen concerns about Rotarix' efficacy raised in an earlier clinical trial and show both vaccines to be effective. News